Skip to main content
Clinical Trials/NCT05041478
NCT05041478RecruitingNot Applicable

Cold Snare Endoscopic Mucosal Resection vs Cold Snare Endoscopic Mucosal Resection With Adjuvant Thermal Therapy to Resection Margins - A Randomised Controlled Trial

Western Sydney Local Health District1 site in 1 country300 target enrollmentStarted: September 19, 2023Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
300
Locations
1
Primary Endpoint
Adenoma recurrence rate (ARR)

Study Overview

Brief Summary

Randomised controlled trial comparing cold snare endoscopic mucosal resection (EMR) with cold snare EMR and adjuvant margin STSC in the complete resection of 15-40mm lateral-spreading adenomas

Detailed Description

Rationale:

Conventional EMR is well-established for the resection of lateral-spreading adenomas and has been shown to be highly efficacious with adjuvant STSC. Cauterisation-related complications occur relatively frequently and while endoscopically treatable, still carry morbidity not seen in current cold snare polypectomy data.

Cold snare polypectomy has an excellent safety profile for smaller polyps, without cauterisation-related adverse events. Limited data on cold EMR for large adenomatous laterally-spreading lesions shows minimal complications. Efficacy, however, is yet to be evaluated in prospective randomised trials. Observational data demonstrates recurrence rates exceeding conventional EMR. Since STSC causes significant reduction in recurrence in conventional EMR, the safety and efficacy of this adjuvant technique, when compared to isolated cold snare EMR, has theoretical advantages in both safety and efficacy.

The safety and efficacy of these two techniques will therefore be compared in a randomised controlled trial.

Hypothesis:

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Masking Description

Blinding

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Any patient undergoing colonoscopy who is older than 18 years of age, has a written consent for trial participation and has at least one laterally spreading lesion meeting the following description:
  • •Localisation in the colon or rectum
  • •Benign adenomatous surface features (Kudo III / IV, Japan NBI Expert Team (JNET) 2a)
  • •Granular or non-granular topography
  • •Paris classification 0-IIa/IIb +/- Is
  • •If present, sessile component may be no greater than 10mm in size.
  • •Polyp size ranging from 15 to 40mm

Exclusion Criteria

  • •Current use of antiplatelet (excluding aspirin) or anticoagulants which have not appropriately been interrupted according to the guidelines.
  • •Known bleeding disorder or coagulopathy.
  • •Pregnancy
  • •History of inflammatory bowel disease
  • •Previously attempted or otherwise non-lifting lesions
  • •Endoscopic features suggestive of submucosal invasion (Kudo Vi/n, JNET 2b / 3) or concurrent colorectal cancer
  • •Lesions involving the ileocaecal valve (ICV), appendiceal oriface or anorectal junction (ARJ)

Arms & Interventions

Cold EMR with adjuvant STSC to margins

Experimental

Standard cold EMR technique with adjuvant snare tip soft coagulation to defect margins

Intervention: Cold Snare Endoscopic mucosal resection with adjuvant snare tip soft coagulation (Procedure)

Cold EMR

Active Comparator

Standard Cold EMR resection technique

Intervention: Cold Snare Endoscopic Mucosal Resection (Procedure)

Outcomes

Primary Outcomes

Adenoma recurrence rate (ARR)

Time Frame: 4-6 months

ARR at first surveillance colonoscopy (SC1) as determined by endoscopic assessment (no visible recurrent adenoma) and histological assessment (scar biopsies)

Complete resection rate (CRR)

Time Frame: 1 day

Determined by endoscopic assessment (no visible residual adenoma) and histological assessment (biopsies of resection margin)

Secondary Outcomes

  • Intra-procedural and post-procedural complication rates(30 days)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Professor Michael Bourke

Professor

Western Sydney Local Health District

Study Sites (1)

Loading locations...

Similar Trials